AR and prostate cancer: Given that germline mutations of DNA repair–deficient prostate cancer have been associated with resistance to abiraterone and enzalutamide38 and that these alterations were recently linked with NED molecular pathways sharing common platinum-sensitivity45, mixed forms between prostate adenocarcinoma and NEPC could be also characterized on the basis of a deficit in DNA damage repair, especially in aggressive CRPC variants with AR CN normal.